This Pot Stock Is Punishing Shareholders

Aurora Cannabis Inc (TSX:ACB) has been recklessly diluting shareholders by overpaying for acquisitions.

| More on:

In 2018, the pot industry has been decidedly mixed. After the euphoria peaked in early January, the TSX marijuana index lost 49% of its value. There are some companies that have flourished, while others have seen their stocks dry up – pun intended.

One company who has self-inflicted wounds is Aurora Cannabis Inc. (TSX:ACB). Aurora started off  the year with a bang. There was a point in early 2018 when the company challenged Canopy Growth Corp. as the largest publicly-listed marijuana company. It didn’t last long.

Whereas Canopy Growth has posted positive returns year-to-date, Aurora is in freefall having lost almost 50% of its value. So what happened?

Share dilution

The answer is simple: share dilution. The company has made several high-profile acquisitions. On May 1, it completed the $1.1 billion deal for CanniMed Therapeutics. Less than a month later, it one-upped itself with it announced a $3.2 billion dollar buyout of MedReleaf Corp. These are the largest purchases in the history of the industry.

Following the closing of the MedReleaf deal, Aurora’s annual cannabis production capacity jumped to 570,000 kilograms — the largest in the industry. Isn’t this supposed to be a positive?

The issue is that these are all-stock deals. I warned investors a couple of times that these all-stock deals almost always benefit the shareholders of the company being acquired. Existing shareholders of the acquirer end up holding the bag. The reason? They see their percentage of ownership in the company shrink.

Need proof? Upon the announcement of the CanniMed deal, Aurora’s share price cratered by almost 40% the month following. Since the MedReleaf deal closed, Aurora’s share price has lost another 12%. President Steven Dobler sold 1.4 million shares the day before the close of the MedReleaf deal. Coincidence? I’ll let you be the judge.

Aurora has made several other smaller purchases over the past few months, all of which further diluted shareholder ownership through the issuance of additional shares, options, and warrants.

Reckless strategy

There is a general sense that Aurora is over-extending itself. The company is racing to be the biggest pot company in the world. Problem is, it’s not a race. I would argue that rushing into deals to grow production capacity can lead the company to overpay.

Case in point, the MedReleaf acquisition. Street consensus was that Aurora overpaid for the company. The worst part? When asked about the numbers behind the deal to justify its valuation, Chief Executive Terry Booth responded with “Metrics.”  Likewise, when asked about the synergies of the deal, Chief Commercial Officer Cam Battley answer was equally concerning: “We don’t have an exact calculation of the synergies.”

These are weak answers, and shareholders should demand more from management. The company should focus on integrating its many acquisitions. The constant issuance of shares is punishing current shareholders and doing nothing for the company’s valuation. In fact, these deals are having the opposite effect. Since Aurora went on its acquisition spree, its market cap has been trending downwards.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Mat Litalien is long Aurora Cannabis Inc.  

More on Investing

how to save money
Investing

The Best TSX Stock for Canadians to Buy With $1,000 Right Now

iShares S&P/TSX 60 Index ETF (TSX:XIU) could be a great starter investment for new investors in Canada.

Read more »

Canadian dollars are printed
Dividend Stocks

Beat the TSX With This Cash-Gushing Dividend Stock

Toronto-Dominion Bank (TSX:TD) stock could do well in the year ahead.

Read more »

monthly desk calendar
Dividend Stocks

Monthly Income: Top Dividend Stocks to Buy in November

Here are two of the best monthly dividend stocks in Canada you can buy in November 2024 and hold for…

Read more »

hand stacks coins
Investing

A Top TSX Stock to Buy Now for Real Wealth Later

Intact Financial (TSX:IFC) stock is a fantastic dividend-growth play for the next 15 years and beyond.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Thursday, November 14

The U.S. wholesale inflation data and Fed chair Jerome Powell’s remarks about the economy will remain on TSX investors’ radar…

Read more »

Man data analyze
Tech Stocks

3 Reasons Celestica Stock Is a Screaming Buy Now

These three reasons make Celestica stock a screaming buy for long-term investors.

Read more »

profit rises over time
Dividend Stocks

These 2 Dow Stocks Are Set to Soar in 2025 and Beyond

Two Dow Jones stocks are screaming buys but Canadians must hold them in an RRSP or RRIF to avoid paying…

Read more »

TFSA (Tax free savings account) acronym on wooden cubes on the background of stacks of coins
Dividend Stocks

How to Use Your TFSA to Earn Ultimate Passive Income

If you have a TFSA, then you have the key to creating ultimate passive income. All you need is a…

Read more »